China Meheco subsidiary receives drug approvals and export certificate

China Meheco's subsidiary, Tianfang Pharmaceutical, received approval from the National Medical Products Administration for Fumarate Vonoprazan chemical active pharmaceutical ingredient. The company invested approximately 11.36 million yuan in R&D for this drug and its preparations.

Tianfang Pharmaceutical also obtained a Certificate of Suitability for Clindamycin Phosphate from the European Directorate for the Quality of Medicines & HealthCare, enabling access to European and other regulated markets.